Metraipolis › archive › dc_5edeb595bfa4

Effects of MDMA-assisted therapy for PTSD on self-experience — Europe PMC PMID:38198456

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/38198456
DOI: 10.1371/journal.pone.0295926
License (as archived): CC0-1.0
Archived: 2026-10-07T11:28:46.833Z
SHA-256 of the archived text: 681bddf427e8e2b1f168fa4863b24464cdc4562ec3c8858ed780253c22b3c4de
Stable URL of this page: https://metraipolis.com/documento/dc_5edeb595bfa4

How to cite

Effects of MDMA-assisted therapy for PTSD on self-experience — Europe PMC PMID:38198456 — Europe PMC (en), https://europepmc.org/article/MED/38198456 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_5edeb595bfa4 (Metraipolis archive dc_5edeb595bfa4, sha256 681bddf427e8e2b1f168fa4863b24464cdc4562ec3c8858ed780253c22b3c4de)

BibTeX

@misc{dc5edeb595bfa4,
  title = {Effects of MDMA-assisted therapy for PTSD on self-experience — Europe PMC PMID:38198456},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38198456},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_5edeb595bfa4; sha256 681bddf427e8e2b1f168fa4863b24464cdc4562ec3c8858ed780253c22b3c4de},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38198456. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MDMA). Primary findings from our randomized, double-blind, placebo-controlled, multi-site Phase 3 clinical trial of participants with severe PTSD (NCT03537014) showed that MDMA-assisted therapy induced significant attenuation in the Clinician-Administered PTSD Scale for DSM-5 compared to Therapy with placebo. Deficits in emotional coping skills and altered self-capacities constitute major obstacles to successful completion of available treatments. The current analysis evaluated the differential effects of MDMA-assisted therapy and Therapy with placebo on 3 transdiagnostic outcome measures and explored the contribution of changes in self-experience to improvement in PTSD scores. Methods: Participants were randomized to receive manualized therapy with either MDMA or placebo during 3 experimental sessions in combination with 3 preparation and 9 integration therapy visits. Symptoms were measured at baseline and 2 months after the last experimental session using the 20-item Toronto Alexithymia Scale (TAS-20), the 26-item Self Compassion Scale (SCS), and the 63-item Inventory of Altered Self-Capacities (IASC). Results: 90 participants were randomized and dosed (MDMA-assisted therapy, n = 46; Therapy with placebo, n = 44); 84.4% (76/90) had histories of developmental trauma, and 87.8% (79/90) had suffered multiple traumas. MDMA-assisted therapy facilitated statistically significant greater improvement on the TAS-20, the SCS, and most IASC factors of interpersonal conflicts; idealization disillusionment; abandonment concerns; identity impairment; self-awareness; susceptibility to influence; affect dysregulation; affect instability; affect skill deficit; tension reduction activities; the only exception was identity diffusion. Conclusion: Compared with Therapy with placebo, MDMA-assisted therapy had significant positive effects on transdiagnostic mental processes of self-experience which are often associated with poor treatment outcome. This provides a possible window into understanding the psychological capacities facilitated by psychedelic agents that may result in significant improvements in PTSD symptomatology.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-01-10).
Identificativi: PMID 38198456 · PMCID PMC10781106 · DOI 10.1371/journal.pone.0295926.
Descrittori MeSH principali: N-Methyl-3,4-methylenedioxyamphetamine; Hallucinogens; Stress Disorders, Post-Traumatic.
Pagina: https://europepmc.org/article/MED/38198456 — https://doi.org/10.1371/journal.pone.0295926. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:17:10.454Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.